Bluebird CEO defends $1.8 million gene therapy price — 'It's really thinking about it differently' [CNBC]
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: CNBC
Bluebird Bio CEO defends $1.8 million price for gene therapy — 'It's really thinking about it differently' Bluebird Bio Bluebird's therapy, Zynteglo, was approved in Europe earlier this month for patients with beta thalassemia who require regular blood transfusions to manage their disease and have no matching donor for a stem cell transplant. The price tag, set Friday, makes the drug the second most expensive in the world behind Swiss drugmaker Novartis $2.1 million gene therapy Leschly reasoned that the one-time treatment is a game changer for patients, giving them a "lifelong benefit" while avoiding costly blood transfusions every few weeks for the rest of their lives. Bluebird said patients will only have to pay $1.8 million if the treatment works. The company proposed a five-year installment plan, with 315,000 euros, or $356,567, paid upfront and additional payments due only if the treatment proves effective. It's a form of value-based pricing, Leschly said. "Neither Novartis' dr
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Barclays PLC from $4.00 to $2.00. They now have an "overweight" rating on the stock.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $0.50 price target on the stock, down previously from $3.00.MarketBeat
BLUE
Earnings
- 11/14/24 - Beat
BLUE
Sec Filings
- 11/14/24 - Form DEFA14A
- 11/14/24 - Form SC
- 11/14/24 - Form S-8
- BLUE's page on the SEC website